These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32163218)

  • 1. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
    Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
    Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin β-D-Glucuronide Plays an Important Role to Keep High Levels of Free-Form Curcumin in the Blood.
    Ozawa H; Imaizumi A; Sumi Y; Hashimoto T; Kanai M; Makino Y; Tsuda T; Takahashi N; Kakeya H
    Biol Pharm Bull; 2017; 40(9):1515-1524. PubMed ID: 28867734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
    Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G
    Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
    Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
    Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin.
    Abe T; Horisawa Y; Kikuchi O; Ozawa-Umeta H; Kishimoto A; Katsuura Y; Imaizumi A; Hashimoto T; Shirakawa K; Takaori-Kondo A; Yusa K; Asakura T; Kakeya H; Kanai M
    Eur J Pharmacol; 2022 Nov; 935():175321. PubMed ID: 36228744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Anthraquinone Derivative C2 Enhances Oxaliplatin-Induced Cell Death and Triggers Autophagy via the PI3K/AKT/mTOR Pathway.
    Li Y; Yan W; Qin Y; Zhang L; Xiao S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.
    Liu G; Khanna V; Kirtane A; Grill A; Panyam J
    FASEB J; 2019 Aug; 33(8):9453-9465. PubMed ID: 31136203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
    Prijovich ZM; Burnouf PA; Chou HC; Huang PT; Chen KC; Cheng TL; Leu YL; Roffler SR
    Mol Pharm; 2016 Apr; 13(4):1242-50. PubMed ID: 26824303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.
    Yu M; Xu C; Zhang H; Lun J; Wang L; Zhang G; Fang J
    Biochem Biophys Res Commun; 2021 Jul; 563():1-7. PubMed ID: 34052504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
    Chen KC; Schmuck K; Tietze LF; Roffler SR
    Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells.
    Liu C; Liu Q; Yan A; Chang H; Ding Y; Tao J; Qiao C
    Cancer Med; 2020 Jun; 9(11):3875-3884. PubMed ID: 32248666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MyD88 in DNA repair and cancer cell resistance to genotoxic drugs.
    Kfoury A; Le Corf K; El Sabeh R; Journeaux A; Badran B; Hussein N; Lebecque S; Manié S; Renno T; Coste I
    J Natl Cancer Inst; 2013 Jul; 105(13):937-46. PubMed ID: 23766530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined anti-cancer effects of curcumin and oxaliplatin on colon carcinoma colo205 cells using transplanted nude mice.
    Zhang N; Hao Y; Liu H; Yu Q; Bo B; Liang J
    Pak J Pharm Sci; 2021 Sep; 34(5(Special)):2021-2025. PubMed ID: 34862868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo.
    Tian F; Fan T; Zhang Y; Jiang Y; Zhang X
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):847-55. PubMed ID: 23017833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo.
    Howells LM; Sale S; Sriramareddy SN; Irving GR; Jones DJ; Ottley CJ; Pearson DG; Mann CD; Manson MM; Berry DP; Gescher A; Steward WP; Brown K
    Int J Cancer; 2011 Jul; 129(2):476-86. PubMed ID: 20839263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NFκB in colon cancer cells and xenograft tumors.
    Chen C; Liu Y; Chen Y; Xu J
    Cancer Biol Ther; 2011 Nov; 12(9):797-807. PubMed ID: 21900746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
    Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
    Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.
    Rajitha B; Nagaraju GP; Shaib WL; Alese OB; Snyder JP; Shoji M; Pattnaik S; Alam A; El-Rayes BF
    Mol Carcinog; 2017 Jan; 56(1):288-299. PubMed ID: 27128654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin synergizes with resveratrol to inhibit colon cancer.
    Majumdar AP; Banerjee S; Nautiyal J; Patel BB; Patel V; Du J; Yu Y; Elliott AA; Levi E; Sarkar FH
    Nutr Cancer; 2009; 61(4):544-53. PubMed ID: 19838927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.